JP2024516825A5 - - Google Patents

Info

Publication number
JP2024516825A5
JP2024516825A5 JP2023566472A JP2023566472A JP2024516825A5 JP 2024516825 A5 JP2024516825 A5 JP 2024516825A5 JP 2023566472 A JP2023566472 A JP 2023566472A JP 2023566472 A JP2023566472 A JP 2023566472A JP 2024516825 A5 JP2024516825 A5 JP 2024516825A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical product
pharmaceutically acceptable
acceptable salt
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516825A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/071967 external-priority patent/WO2022232808A1/en
Publication of JP2024516825A publication Critical patent/JP2024516825A/ja
Publication of JP2024516825A5 publication Critical patent/JP2024516825A5/ja
Pending legal-status Critical Current

Links

JP2023566472A 2021-04-29 2022-04-28 トポイソメラーゼi阻害剤のペプチドコンジュゲートの投与レジメン Pending JP2024516825A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181640P 2021-04-29 2021-04-29
US63/181,640 2021-04-29
PCT/US2022/071967 WO2022232808A1 (en) 2021-04-29 2022-04-28 Dosing regimens of peptide conjugates of topoisomerase i inhibitors

Publications (2)

Publication Number Publication Date
JP2024516825A JP2024516825A (ja) 2024-04-17
JP2024516825A5 true JP2024516825A5 (cg-RX-API-DMAC7.html) 2025-05-09

Family

ID=81749580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566472A Pending JP2024516825A (ja) 2021-04-29 2022-04-28 トポイソメラーゼi阻害剤のペプチドコンジュゲートの投与レジメン

Country Status (12)

Country Link
US (1) US20240226308A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329817A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516825A (cg-RX-API-DMAC7.html)
KR (1) KR20240019097A (cg-RX-API-DMAC7.html)
CN (1) CN117897175A (cg-RX-API-DMAC7.html)
AU (1) AU2022267389A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218253A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003187A1 (cg-RX-API-DMAC7.html)
IL (1) IL308052A (cg-RX-API-DMAC7.html)
MX (1) MX2023012779A (cg-RX-API-DMAC7.html)
TW (1) TW202308696A (cg-RX-API-DMAC7.html)
WO (1) WO2022232808A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
CA3032186C (en) 2010-07-13 2022-04-26 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
SG10201913073YA (en) * 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20210106648A1 (en) * 2019-10-11 2021-04-15 TOBEBIO Novel Drug Laboratory Co., Ltd. Synergistic combination of chemotherapy and peptide for treating cancer

Similar Documents

Publication Publication Date Title
JP2021510725A5 (cg-RX-API-DMAC7.html)
JP2011511072A (ja) 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用
RU2014152107A (ru) Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака
RU2014152115A (ru) Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака
JP5579715B2 (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
JP2018528185A5 (cg-RX-API-DMAC7.html)
TW201914592A (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
CN117157106A (zh) 药物在治疗肿瘤疾病中的应用
JP2008540364A5 (cg-RX-API-DMAC7.html)
CN121001749A (zh) 药物偶联物治疗肿瘤疾病的用途及方法
Fukuoka et al. Clinical studies of irinotecan alone and in combination with cisplatin
JP2023546316A5 (cg-RX-API-DMAC7.html)
EP1711188B1 (en) Anti-cancer therapies
JP5881782B2 (ja) 医薬組成物又は組合せ剤
CN105263499B (zh) 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
EP2117539B1 (en) A method of administering an antitumor compound
JP7311177B2 (ja) A-NOR-5αアンドロスタン薬物と抗がん薬物との併用
JP2023550043A5 (cg-RX-API-DMAC7.html)
AU2018234141A1 (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
CN107519171A (zh) 洛匹那韦减轻伊立替康毒性的医药新用途
CN1774249A (zh) 伊立替康在治疗耐受性乳腺癌中的应用
HK1213475B (en) Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy
CN121127270A (zh) 药物偶联物治疗肿瘤疾病的用途及方法
JP2023514742A5 (cg-RX-API-DMAC7.html)
HK1087011A (en) Use of irinotecan for treatment of resistant breast cancer